FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166584881> ?p ?o ?g. }

• W2166584881 endingPage "2476" @default.
• W2166584881 startingPage "2472" @default.
• W2166584881 abstract "No AccessJournal of UrologyInvestigative Urology1 Nov 2009Multidrug Resistance in a Urothelial Cancer Cell Line After 1-Hour Mitomycin C Exposureis companion ofClinical Outcomes and Recurrence Predictors of Lymph Node Positive Urothelial Cancer After CystectomyLocation of the Primary Tumor is Not an Independent Predictor of Cancer Specific Mortality in Patients With Upper Urinary Tract Urothelial CarcinomaPredicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model Narendrakumar Birare, Bashir A. Lwaleed, and Alan J. Cooper Narendrakumar BirareNarendrakumar Birare More articles by this author , Bashir A. LwaleedBashir A. Lwaleed More articles by this author , and Alan J. CooperAlan J. Cooper More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2009.07.007AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: A factor pertinent to the design of cancer chemotherapy is multidrug resistance. Research in this area conventionally involves in vitro models using resistant cell lines generated by continuous low dose drug exposure for many months, unlike the exposure experienced by residual superficial bladder cancer cells during chemotherapy adjuvant to resection. Recently we noted a measure of multidrug resistance induced by 3 short exposures to mitomycin C during 10 weeks. We currently report detectable functional resistance after a single 1-hour insult. Materials and Methods: RT112 bladder cancer cells (Catalog No. ACC 418, Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany) were exposed to a range of mitomycin C concentrations for 1 hour. Cells regrew in 3 of 24 cultures at 15.6, 3.91 and 0.98 mg/ml exposure. These cells were subjected to 3 functional tests of cross resistance to epirubicin, including MTT cytotoxicity assay, quantitative accumulation by flow cytometry and nuclear uptake or exclusion by live cell fluorescence microscopy. Results: MTT assay and flow cytometry revealed clear indications of resistance. Intracellular distribution, in which nuclear exclusion indicates resistance, was distinctively resistant in 1 subline and another 2 were equivocal. Conclusions: Results indicate that some multidrug resistance potential exists even in a cloned cell line that is capable of surviving 1 short drug exposure and expanding after that insult. The exposures used are consistent with those probably experienced by many superficial transitional cell carcinoma cells during an intravesical chemotherapy application. The result gives added weight to considering multidrug resistance induction in dose scheduling or drug combinations for topical chemotherapy. References 1 : The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol1996; 155: 1233. Link, Google Scholar 2 : Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukaemia. Cancer Res1979; 39: 2200. Google Scholar 3 : Establishment and characterization of a doxorubicin-resistant human bladder cancer cell line (MGH-U1R). J Urol1988; 140: 410. Link, Google Scholar 4 : The efflux of anthracyclines in multidrugresistant cell lines. Biochem Pharmacol1993; 46: 1317. Google Scholar 5 : Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C. J Urol2007; 178: 2171. Link, Google Scholar 6 : Intravesical chemotherapy with epirubicin: a dose response study. J Urol1999; 161: 1490. Link, Google Scholar 7 : The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter. Int J Cancer1993; 54: 456. Google Scholar 8 : Determination and reversal of resistance to epirubicin intravesical chemotherapy: A flow cytometric model. Br J Urol1996; 77: 819. Google Scholar 9 : Estramustine reversal of resistance to intravesical epirubicin chemotherapy. Eur Urol1999; 35: 327. Google Scholar 10 : Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation. Anticancer Res2001; 21: 847. Google Scholar 11 : Progesterone: a novel adjunct to intravesical chemotherapy. BJU Int2002; 90: 736. Google Scholar 12 : Furosemide reverses multidrug resistance status in bladder cancer cells in vitro. J Clin Pathol2006; 59: 912. Google Scholar 13 : Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumours. Scand J Urol Nephrol1991; 25: 25. Google Scholar 14 : Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone: The Kyushu University Urological Oncology Group. Cancer Chemother Pharmacol1998; 42: 367. Google Scholar 15 : Intravesical instillation chemotherapy of adriamycin with or without verapamil for the treatment of superficial bladder cancer: the final results of a collaborative randomized trial. Cancer Chemother Pharmacol1994; 35: 69. Google Scholar 16 : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem1993; 62: 385. Google Scholar 17 : The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines. BJU Int2005; 95: 1091. Google Scholar 18 : Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines. Br J Cancer1996; 74: 906. Google Scholar 19 : Nuclear transport as an ultimate step of multidrug resistance. Life Sci1999; 65: 2343. Google Scholar Department of Biomedical Sciences, University of Portsmouth, Portsmouth and Department of Urology, Southampton University Hospitals National Health Service Trust (BAL), Southampton, United Kingdom© 2009 by American Urological AssociationFiguresReferencesRelatedDetailsRelated articlesJournal of Urology15 Sep 2009Clinical Outcomes and Recurrence Predictors of Lymph Node Positive Urothelial Cancer After CystectomyJournal of Urology16 Sep 2009Location of the Primary Tumor is Not an Independent Predictor of Cancer Specific Mortality in Patients With Upper Urinary Tract Urothelial CarcinomaJournal of Urology16 Sep 2009Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model Volume 182Issue 5November 2009Page: 2472-2476 Advertisement Copyright & Permissions© 2009 by American Urological AssociationKeywordsmitomycindrug resistancemultipleurinary bladderurotheliumcarcinomatransitional cellMetricsAuthor Information Narendrakumar Birare More articles by this author Bashir A. Lwaleed More articles by this author Alan J. Cooper More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2166584881 created "2016-06-24" @default.
• W2166584881 creator A5026234399 @default.
• W2166584881 creator A5032528930 @default.
• W2166584881 creator A5040956604 @default.
• W2166584881 date "2009-11-01" @default.
• W2166584881 modified "2023-09-25" @default.
• W2166584881 title "Multidrug Resistance in a Urothelial Cancer Cell Line After 1-Hour Mitomycin C Exposure" @default.
• W2166584881 cites W1548546032 @default.
• W2166584881 cites W1982401140 @default.
• W2166584881 cites W1985071554 @default.
• W2166584881 cites W2013277194 @default.
• W2166584881 cites W2037468006 @default.
• W2166584881 cites W2040405175 @default.
• W2166584881 cites W2049901118 @default.
• W2166584881 cites W2077794507 @default.
• W2166584881 cites W2082095819 @default.
• W2166584881 cites W2082676081 @default.
• W2166584881 cites W2087107415 @default.
• W2166584881 cites W2089464224 @default.
• W2166584881 cites W2118234018 @default.
• W2166584881 cites W2123614023 @default.
• W2166584881 cites W2162804615 @default.
• W2166584881 cites W2168662668 @default.
• W2166584881 cites W2418783278 @default.
• W2166584881 doi "https://doi.org/10.1016/j.juro.2009.07.007" @default.
• W2166584881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19765756" @default.
• W2166584881 hasPublicationYear "2009" @default.
• W2166584881 type Work @default.
• W2166584881 sameAs 2166584881 @default.
• W2166584881 citedByCount "3" @default.
• W2166584881 countsByYear W21665848812013 @default.
• W2166584881 countsByYear W21665848812014 @default.
• W2166584881 countsByYear W21665848812015 @default.
• W2166584881 crossrefType "journal-article" @default.
• W2166584881 hasAuthorship W2166584881A5026234399 @default.
• W2166584881 hasAuthorship W2166584881A5032528930 @default.
• W2166584881 hasAuthorship W2166584881A5040956604 @default.
• W2166584881 hasConcept C114851261 @default.
• W2166584881 hasConcept C121608353 @default.
• W2166584881 hasConcept C126322002 @default.
• W2166584881 hasConcept C126894567 @default.
• W2166584881 hasConcept C133936738 @default.
• W2166584881 hasConcept C141071460 @default.
• W2166584881 hasConcept C143998085 @default.
• W2166584881 hasConcept C2776694085 @default.
• W2166584881 hasConcept C2779338040 @default.
• W2166584881 hasConcept C2780352672 @default.
• W2166584881 hasConcept C2780849966 @default.
• W2166584881 hasConcept C2910041100 @default.
• W2166584881 hasConcept C3020745361 @default.
• W2166584881 hasConcept C502942594 @default.
• W2166584881 hasConcept C71924100 @default.
• W2166584881 hasConcept C86803240 @default.
• W2166584881 hasConcept C89423630 @default.
• W2166584881 hasConceptScore W2166584881C114851261 @default.
• W2166584881 hasConceptScore W2166584881C121608353 @default.
• W2166584881 hasConceptScore W2166584881C126322002 @default.
• W2166584881 hasConceptScore W2166584881C126894567 @default.
• W2166584881 hasConceptScore W2166584881C133936738 @default.
• W2166584881 hasConceptScore W2166584881C141071460 @default.
• W2166584881 hasConceptScore W2166584881C143998085 @default.
• W2166584881 hasConceptScore W2166584881C2776694085 @default.
• W2166584881 hasConceptScore W2166584881C2779338040 @default.
• W2166584881 hasConceptScore W2166584881C2780352672 @default.
• W2166584881 hasConceptScore W2166584881C2780849966 @default.
• W2166584881 hasConceptScore W2166584881C2910041100 @default.
• W2166584881 hasConceptScore W2166584881C3020745361 @default.
• W2166584881 hasConceptScore W2166584881C502942594 @default.
• W2166584881 hasConceptScore W2166584881C71924100 @default.
• W2166584881 hasConceptScore W2166584881C86803240 @default.
• W2166584881 hasConceptScore W2166584881C89423630 @default.
• W2166584881 hasIssue "5" @default.
• W2166584881 hasLocation W21665848811 @default.
• W2166584881 hasLocation W21665848812 @default.
• W2166584881 hasOpenAccess W2166584881 @default.
• W2166584881 hasPrimaryLocation W21665848811 @default.
• W2166584881 hasRelatedWork W116385386 @default.
• W2166584881 hasRelatedWork W1964524236 @default.
• W2166584881 hasRelatedWork W1970119198 @default.
• W2166584881 hasRelatedWork W2376268425 @default.
• W2166584881 hasRelatedWork W2605800150 @default.
• W2166584881 hasRelatedWork W4236264006 @default.
• W2166584881 hasRelatedWork W4243076189 @default.
• W2166584881 hasRelatedWork W4313197990 @default.
• W2166584881 hasRelatedWork W629149090 @default.
• W2166584881 hasRelatedWork W2118673085 @default.
• W2166584881 hasVolume "182" @default.
• W2166584881 isParatext "false" @default.
• W2166584881 isRetracted "false" @default.
• W2166584881 magId "2166584881" @default.
• W2166584881 workType "article" @default.